ProQR Therapeutics NV (PRQR)
1.435
+0.02
(+1.77%)
USD |
NASDAQ |
Jun 11, 14:51
ProQR Therapeutics Gross Profit Margin (Quarterly) : 65.86% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 65.86% |
| December 31, 2025 | 85.52% |
| September 30, 2025 | 76.72% |
| June 30, 2025 | 82.32% |
| March 31, 2025 | 85.00% |
| December 31, 2024 | 84.42% |
| September 30, 2024 | 82.10% |
| June 30, 2024 | 88.72% |
| March 31, 2024 | 84.47% |
| December 31, 2023 | 0.00% |
| Date | Value |
|---|---|
| September 30, 2023 | 0.00% |
| June 30, 2023 | 0.00% |
| March 31, 2023 | 0.00% |
| December 31, 2022 | 10.27% |
| September 30, 2022 | 0.00% |
| June 30, 2022 | 0.00% |
| March 31, 2022 | 0.00% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Pharming Group NV | 90.83% |
| NewAmsterdam Pharma Co. NV | 97.96% |
| Kamada Ltd. | 42.25% |
| Syndax Pharmaceuticals, Inc. | 95.93% |
| Opus Genetics, Inc. | 99.40% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -79.31% |
| Return on Assets | -36.71% |
| Return on Invested Capital | -63.42% |
| Profit Margin (Quarterly) | -658.3% |
| Operating Margin (Quarterly) | -671.4% |
| Return on Net Operating Assets | -282.6% |